EUVIMEDEUVIMED entdecken
Crossref

Blood-based Biomarkers in Cervical Cancer: The Emerging Role of Circulating Human Papillomavirus and Tumor Deoxyribonucleic Acid

Neeta Verma, Vijayta Singh

Annals of African Medicine · 19.06.2026

DOI: 10.4103/aam.aam_138_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of African Medicine, online erschienen am 19.06.2026. Verfasst von Neeta Verma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer (CC) remains a major global health burden, particularly in low- and middle-income countries (LMICs), where access to timely diagnosis and surveillance is limited. Circulating tumor deoxyribonucleic acid (ctDNA), including virus-derived human papillomavirus (HPV) ctDNA, offers a promising, noninvasive biomarker for diagnosis, prognosis, and treatment monitoring in CC. A comprehensive literature review of clinical studies, meta-analyses, and ongoing trials evaluating the role of ctDNA in CC. The key aspects analyzed included cell-free HPV (ctHPV) DNA detection, mutation and methylation profiling, correlation with tumor burden and treatment response, technical limitations, and emerging applications. ctHPV DNA is detectable in 60%–95% of patients with CC, particularly in advanced-stage disease. It correlates with tumor size, FIGO stage, lymph node involvement, and treatment efficacy. Serial ctDNA monitoring has demonstrated prognostic value, with persistent ctDNA posttreatment predicting early relapse. In addition, ctDNA-based mutation (e.g. PIK3CA and TP53) and methylation profiling (e.g. CADM1 and PAX1) show utility for molecular characterization and resistance tracking. However, limitations include low sensitivity in early-stage disease, assay variability, lack of standardization, and limited accessibility in LMICs. ctDNA represents a transformative tool in CC care, enabling real-time, tumor-specific insights with broad diagnostic and prognostic implications. Future efforts should focus on prospective validation, integration with imaging and artificial intelligence, and development of cost-effective ctHPV DNA screening panels, particularly for underserved populations.

Schlagwörter

Stichwörter der Autor:innen

ADN tumoral circulantCancer du col de l’utérusCervical cancerbiopsie liquidecirculating tumor deoxyribonucleic acidhuman papillomavirusliquid biopsymethylationméthylationpapillomavirus humainsuivi thérapeutiquetreatment monitoring

Autor:innen und Institutionen

  • Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India.
  • Department of Pathology, Maharaja Suhel Dev Autonomous State Medical College, Bahraich, Uttar Pradesh, India.

Zitieren

APA

Verma, N., & Singh, V. (2026). Blood-based Biomarkers in Cervical Cancer: The Emerging Role of Circulating Human Papillomavirus and Tumor Deoxyribonucleic Acid. Annals of African Medicine. https://doi.org/10.4103/aam.aam_138_26

Vancouver

Verma N, Singh V. Blood-based Biomarkers in Cervical Cancer: The Emerging Role of Circulating Human Papillomavirus and Tumor Deoxyribonucleic Acid. Annals of African Medicine. 2026. doi:10.4103/aam.aam_138_26

BibTeX
@article{Verma2026,
  author = {Verma, Neeta and Singh, Vijayta},
  title = {Blood-based Biomarkers in Cervical Cancer: The Emerging Role of Circulating Human Papillomavirus and Tumor Deoxyribonucleic Acid},
  journal = {Annals of African Medicine},
  year = {2026},
  doi = {10.4103/aam.aam_138_26}
}
Kostenlos starten →